The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Risk factors for hemorrhagic events in patients with polycythemia vera
|
Hemorrhagic events are a life-threatening complication that occur in 3–8% of patients with PV.1 A retrospective analysis assessed the association of clinical characteristics and hemorrhagic events in 267 patients with PV.1 Results from this analysis were published in Hematology by Furuya et al.1 |
| Key learnings |
| At a median follow-up of 4.8 years, post-diagnosis hemorrhagic events occurred in 8.6% of patients. There was a higher rate of hemorrhagic events in patients aged <60 years vs patients aged ≥60 years (16.7% vs 5.8%; p = 0.0012). |
| In the univariate analysis, WBC count ≥15.0 × 109/L (p = 0.002), palpable splenomegaly (p = 0.029), and JAK2V617F allele burden ≥80% (p = 0.003) were associated with hemorrhagic events among patients aged <60 years. |
| Multivariate analysis showed that JAK2V617F allele burden ≥80% in patients aged <60 years was associated with an increased risk of hemorrhagic events (HR, 9.394; 95% CI, 1.046–84.380; p = 0.046). |
| Results from this analysis identify potential risk factors for hemorrhagic events in younger patients with PV. Further studies are warranted to explore if therapies that reduce JAK2V617F allele burden may reduce the incidence of hemorrhagic events. |
Abbreviations: CI, confidence interval; HR, hazard ratio; PV, polycythemia vera; WBC, white blood cell.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
